The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc : AMENDMENT 18-Nov-2020 / 18:42 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 **AMENDMENT TO SECTION 2(a) SUBMITTED ON 3 NOVEMBER 2020** PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: ...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Horizon Discovery Group plc 03-Nov-2020 / 15:04 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of inte...
Horizon Discovery Group plc Results for the Six Months Ended 30 June 2020 RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2020 Cambridge, UK, 17 August 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its unaudited results for the six months ended 30 June 2020. Group Financial Highlights Reported revenue of £22.4m (HY19:...
Horizon Discovery Group plc - Horizon Discovery Group plc Half Year Trading Update Horizon Discovery Group plc Half Year Trading Update Business remains robust with sustained recovery to 2019 levels as demand for Horizon’s products and services remains highGroup is confident of a return to growth in H2 2020Capital markets webinar 15:00 BST today – dial in details below Cambridge, UK, 29 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to ...
Two Directors at Horizon Discovery Group bought 104,850 shares at 101p. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Horizon Discovery Group plc Full Year Unaudited Results for the Twelve Months Ended 31 December 2019 Horizon Discovery Group plcFull Year Unaudited Results for the Twelve Months Ended 31 December 2019 Cambridge, UK, 27 April 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces its full year unaudited financial results for the twelve months ended 31 Decemb...
Horizon Discovery Group plc: Pre-Close Trading Update Horizon Discovery Group plc Pre-Close Trading Update Full year 2019 Group unaudited revenues from continuing operations expected to increase by approximately 8% to approximately £58.3 millionFull year 2019 Group unaudited reported revenues expected to increase by approximately 7% to approximately £62.9 million Cambridge, UK, 4 February 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon" “the Group” or “the Company”), a global leader in the application of gene editing and gene modulation technologies, today provides an unaudited p...
Exercises Option to Exclusively License Base Editing Technology from Rutgers, The State University of New Jersey Horizon Discovery Group plc Exercises Option to Exclusively License Base Editing Technology from Rutgers, The State University of New Jersey Cambridge, UK, 14 January 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Group”), a global leader in the application of gene editing and gene modulation technologies, announces that it has exercised its option to exclusively license a novel Base Editing technology from Rutgers, The State University of New Jersey (US), fo...
Horizon Discovery Group plc to Present at 38th Annual J.P. Morgan Healthcare Conference Horizon Discovery Group plc to Present at 38th Annual J.P. Morgan Healthcare Conference Cambridge, UK, 18 December 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Group”), a global leader in the application of gene editing and gene modulation technologies, today announces that Terry Pizzie, Horizon's Chief Executive Officer, will provide an overview and company update as well as host meetings with investors, at the 38th Annual J.P. Morgan Healthcare Conference which is being held in San ...
Horizon Discovery Group plc: Results for the Six Months Ended 30 June 2019 RNS Horizon Discovery Group plcResults for the Six Months Ended 30 June 2019 Cambridge, UK, 16 September 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a global leader in the application of gene editing and gene modulation technologies, today announces its results for the six months ended 30 June 2019. Group Financial highlights Reported revenue of £28.6m an increase of 13.9% on the prior year (HY18: £25.1m) or growth of 8.8% on a constant currency basis1Gross margin inc...
CAMBRIDGE, England--(BUSINESS WIRE)-- Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a company driving the application of gene editing and gene modulation within the global life science market, today announced that Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon’s optimized SMARTvector™ shRNA technology. The Phase 1 trial will be the f...
Horizon Discovery to Present at the 2019 Cowen Health Care Conference Horizon Discovery Group plc Horizon Discovery to Present at the 2019 Cowen Health Care Conference Cambridge, UK, 11 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group" or "Company"), a global leader in the application of gene editing and gene modulation technologies, today announces that Terry Pizzie, Horizon’s Chief Executive Officer, will provide an overview and company update, and host meetings with investors at the 39th Annual Cowen Health Care Conference. Details of the presentation are a...
Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology Horizon Discovery Group plc Horizon Discovery and Rutgers University form exclusive partnership to develop next generation novel gene editing technology Horizon will work with Rutgers University to develop and commercialise base editing platform for therapeutic and research applicationsNew gene editing technology builds on CRISPR and has the potential to assist in the development and treatment of a number of genetic diseases and cancers Cambridge, UK...
Horizon Discovery Group Plc: Interim Results for the Six Months Ended 30 June 2018 HORIZON DISCOVERY GROUP PLC(“Horizon”, “the Group” or “the Company”) Interim Results for the Six Months Ended 30 June 2018 Accelerating revenue growth and prioritising core markets Cambridge, UK, 17 September 2018: Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces its interim results for the six months ended 30 June 2018. Financial Highlights H1 18 H1 17 At constant currency1Growth As reportedGrowth As rep...
CAMBRIDGE, England--(BUSINESS WIRE)-- Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Group”), a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND) filing with the United States Food and Drug Administration (USFDA). This successful filing enhances Horizon’s market opportunity by demonstrating that the cells...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.